Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier

被引：59

作者：

De Rosa, Giuseppe ^{[1
]}

Salzano, Giuseppina ^{[1
]}

Caraglia, Michele ^{[2
]}

Abbruzzese, Alberto ^{[2
]}

机构：

[1] Univ Naples Federico II, Dept Pharmaceut & Toxicol Chem, I-80131 Naples, Italy

[2] Univ Naples 2, Dept Biochem & Biophys, I-80138 Naples, Italy

来源：

CURRENT DRUG METABOLISM | 2012年 / 13卷 / 01期

关键词：

Brain delivery; drug delivery; drug targeting; liposomes; nanoparticles; SOLID LIPID NANOPARTICLES; PEGYLATED POLYCYANOACRYLATE NANOPARTICLES; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; STERICALLY STABILIZED LIPOSOMES; DENSITY-LIPOPROTEIN RECEPTOR; PLASMA-PROTEIN ADSORPTION; CENTRAL-NERVOUS-SYSTEM; DRUG-DELIVERY; IN-VIVO; MULTIPLE-SCLEROSIS;

D O I：

10.2174/138920012798356943

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

The possibility to treat central nervous system (CNS) disorders is strongly limited by the poor access of many therapeutic agent to the target tissues. This is mainly due to the presence of the blood-brain barrier (BBB), formed by a complex interplay of endothelial cells, astrocyte and pericytes, through which only selected molecules can passively diffuse to reach CNS. Drug pharmacokinetics and biodistribution can be changed by using nanotechnology, in order to improve drug accumulation into the action site and to limit the drug release in the healthy tissues. When the CNS diseases are characterised by BBB altered permeability, an enhanced drug delivery into the brain can be achieved by using nanocarriers. Moreover, modification of nanocarrier surface with specific endogenous or exogenous ligands can promote enhanced BBB crossing, also in case of unaltered endothelium. This review summarizes the most meaningful advances in the field of nanotechnology for brain delivery of therapeutics.

引用

页码：61 / 69

页数：9

共 103 条

[1]

Abbruzzese A., 2010, Italian Patent, Patent No. [NA2010A000046, 2010000046]

[2]

Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26 [J].